What did Jefferies do on March 12, 2026 regarding the VKTX analyst rating?

Jefferies reiterated a **Buy** on **Viking Therapeutics (VKTX)** on March 12, 2026, calling the company in “execution mode” and issuing no new price target.

Does the March 12 note include a VKTX price target?

No. The Jefferies note reiterated a Buy but did not publish a new **VKTX price target**, so investors should rely on upcoming company milestones for guidance.

How should investors interpret a maintained Buy in the VKTX analyst rating?

A maintained Buy signals continued analyst confidence in execution and potential upside, but not a fresh catalyst; investors should watch clinical or commercial milestones before changing positions.

What is Meyka AI’s current grade for VKTX and what does it reflect?

Meyka AI rates **VKTX with a grade of B**, reflecting S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus; this is informational, not investment advice.

Analyst Ratings

Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026

ByHuzaifa Zahoor March 13, 2026March 13, 2026

Jefferies reiterated a Buy on Viking Therapeutics, Inc. (VKTX) on March 12, 2026, marking a maintained endorsement that keeps the stock on growth-watch lists. The VKTX analyst rating from Jefferies emphasizes that the company is in “execution mode” this year, signaling operational milestones rather than valuation revisions. For investors the maintained Buy confirms analyst confidence without introducing new price targets. Meyka AI, an AI-powered market analysis platform, tracks this action as part of real-time coverage.